stockrow
Monday 9 November 2026
Export ADGM’s income statement to Excel — free account
Adagio Medical Holdings, Inc.
ADGMAdagio Medical Holdings, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $602,000.00, up 100.7% from fiscal 2023.
- Revenue
- −33.5%
- EPS
- −15.4%
- Free cash flow
- −12.9%
- Total debt
- +46.6%
Quarter to June 2026, against a year earlier
0.06
0.00
0.00%
Follow ADGM
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 1 | — | 1 | +100.7% | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | (335.33) | (451.16) | 0.00 | 0.00 | +335.3 pt | ||||||
| EBT | — | — | — | 0 | 0 | (7) | 1 | (37) | (75) | (25) | (27) | +250.6% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (12,196.67) | (12,465.28) | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | 0 | 0 | (7) | 1 | (37) | (75) | (25) | (27) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.39 | 0.04 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | 0.00 | (1.81) | 0.29 | (48.14) | (4.81) | (1.51) | (1.43) | n/m | ||||||
| Cash flow | — | — | — | 0.00 | 0.00 | (0.29) | (0.13) | (33.75) | (1.89) | (1.15) | (0.74) | n/m | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.45) | (0.11) | (0.02) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | 0.00 | 0.00 | (0.29) | (0.13) | (34.20) | (2.00) | (1.17) | (0.75) | n/m | ||||||
| Book value | — | — | — | 0.00 | 0.00 | (2.84) | (2.31) | (53.36) | 1.28 | 0.75 | (0.02) | n/m | ||||||
| Shares, m | — | — | — | — | 19 | 4 | 4 | 1 | 16 | 17 | 19 | (2.9%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 27.19 | — | 2.21 | 13.6 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.82 | — | 0.00 | 0.4 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 19.70 | — | 30.61 | 9.8 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (0.27) | (0.38) | — | (1.11) | (0.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | 0 | 0 | (1) | 0 | (26) | (29) | (19) | (17) | n/m | |||||
| Capex | — | — | — | — | — | — | — | 0 | (2) | 0 | 0 | +4.9% | ||||||
| Free cash flow | — | — | — | 0 | 0 | (1) | 0 | (26) | (31) | (19) | (17) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | 0 | (5) | (6) | (42) | 18 | 12 | 3 | n/m | |||||
| Net debt | — | — | — | — | — | (1) | 0 | (1) | (5) | 4 | 17 | n/m | ||||||
| Shareholders’ equity | — | — | — | 0 | 0 | (10) | (9) | (41) | 20 | 12 | 0 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (63.53) | (31.76) | (8.72) | 0.71 | (46.14) | (271.53) | (54.71) | (77.80) | +8.8 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (341.51) | (83.74) | (74.60) | (83.7) pt | ||||||
| ROE | — | — | — | 100.00 | 100.00 | 127.31 | (11.27) | 52.02 | 133.87 | (155.25) | (657.76) | (255.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 71 | 41 | — | (42.3%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.01 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2024 · latest quarter Dec 2024 · fundamentals updated 26 Oct 2026
Adagio Medical Holdings, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | +20.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IVF INVO Fertility, Inc | $2.6M | — (loss-making) | — (loss-making) | +16.73% (above 0%: growing) | n/m | +35.07% (above 0%: growing) | 35.06% | (59.28%) | Compare |
| CODX Co-Diagnostics, Inc. | $2.4M | — (loss-making) | — (loss-making) | +1.96% (above 0%: growing) | n/m | +17.47% (above 0%: growing) | 72.73% | (3,733.17%) | Compare |
| ICCM IceCure Medical Ltd. | $2.3M | — (loss-making) | — (loss-making) | −0.69% (below 0%: shrinking) | n/m | +3.88% (above 0%: growing) | 32.38% | (466.19%) | Compare |
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | — (loss-making) | — | — | n/m | −1.05% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ADGM Adagio Medical Holdings, Inc. | $1.8M | — (loss-making) | — | −33.50% (below 0%: shrinking) | n/m | −12.86% (below 0%: shrinking) | 0.00% | 0.00% | |
| NXL Nexalin Technology, Inc. | $1.7M | — (loss-making) | — (loss-making) | −82.72% (below 0%: shrinking) | n/m | −97.23% (below 0%: shrinking) | 72.95% | (18,420.49%) | Compare |
| GCTK GlucoTrack, Inc. | $1.7M | — (loss-making) | — (loss-making) | +342.48% (above 0%: growing) | n/m | +3.42% (above 0%: growing) | 0.00% | 0.00% | Compare |
| DHAI DIH Holding US, Inc. | $1.6M | — (loss-making) | — | −30.67% (below 0%: shrinking) | n/m | −167.90% (below 0%: shrinking) | 50.33% | (33.62%) | Compare |
| Median of peers | $2.2M | — | — | +0.64% | — | +3.65% | 33.72% | (46.45%) |
Pay and ownership Proxy statement filed 13 October 2026
Ownership
Directors and executive officers, together
8.87%
Entities affiliated with Perceptive Advisors LLC
47.98%
Alyeska Master Fund, L.P.
9.26%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement